SELLAS LIFE SCIENCES GROUP I ($SLS) posted quarterly earnings results on Thursday, March 20th. The company reported earnings of -$0.08 per share, beating estimates of -$0.11 by $0.03. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $SLS stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
SELLAS LIFE SCIENCES GROUP I Hedge Fund Activity
We have seen 15 institutional investors add shares of SELLAS LIFE SCIENCES GROUP I stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BROOKLYN FI, LLC added 594,919 shares (+inf%) to their portfolio in Q4 2024, for an estimated $618,715
- CITADEL ADVISORS LLC added 437,998 shares (+925.6%) to their portfolio in Q4 2024, for an estimated $455,517
- ANSON FUNDS MANAGEMENT LP added 398,431 shares (+50.2%) to their portfolio in Q4 2024, for an estimated $414,368
- DIAMETRIC CAPITAL, LP removed 160,194 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $166,601
- GEODE CAPITAL MANAGEMENT, LLC added 128,355 shares (+21.2%) to their portfolio in Q4 2024, for an estimated $133,489
- UBS GROUP AG added 127,821 shares (+inf%) to their portfolio in Q4 2024, for an estimated $132,933
- RENAISSANCE TECHNOLOGIES LLC removed 92,937 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $96,654
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
